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Malignant mesothelioma is a very rare [1] but often
fatal type of testicular malignancy that originates
from mesenchymal tissue [1–4]. It usually presents as
an incidental finding at the time of hydrocele surgery
[4], particularly in patients with prior exposure to
asbestos [5–7]. Here, we describe a Taiwanese patient
with malignant mesothelioma of the tunica vaginalis,
together with a review of the literature.
CASE PRESENTATION
A 67-year-old man, who was previously diagnosed
with infected right hydrocele in 2004 and had long-
standing bilateral hydrocele for 30 years, visited our
clinics with presentation of painless enlargement of the
right scrotum for 2 months. Grossly, the tumor had a
size of 8×10×15cm and occupied the whole right scro-
tum up to the right external inguinal canal. Ultrasonog-
raphy revealed left hydrocele and heterogeneous
right testicular tumor. The subsequent abdominal
and pelvic computerized tomography (CT) demon-
strated a localized heterogeneous right scrotal tumor
without evidence of local lymphadenopathy (Figure 1).
Elevated serum β-HCG (27.5 mIU/mL) was detected.
Surgical exploration through scrotal incision was
performed. The stony hard lesion with purulent dis-
charge had destroyed the right testicle and had in-
vaded the right external inguinal canal. Local resection
was done because of chronic inflammation of thick-
ening tunica vaginalis, as confirmed by frozen section
examination. Pus culture grew enterococcus species.
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Malignant mesothelioma of the tunica vaginalis testis is a rare but often fatal malignancy. Here,
we report one patient with locally advanced disease who has a history of asbestos exposure. We
review the literature concerning current management strategies of the disease. Radical surgery
plus adjuvant radiotherapy seems to provide the best results.
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Figure 1. Computed tomography of the testis shows one hetero-
geneous tumor (arrow) involving the scrotal wall and invading
the right testicle (asterisk).
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However, pathology demonstrated malignant meso-
thelioma arising from the tunica vaginalis of the testis
(Figure 2). Histopathology was characterized by a
biphasic pattern with admixed epithelial and spindle
cell proliferation (Figure 3). Immunohistochemical
staining showed CK (++) (Figure 4A) and EMA (++)
(Figure 4B) positivity in epithelial nests, while the
spindle cell was positive for vimentin (++) (Figure
4C) and negative for desmin (−). Because of poor
wound healing, wide resection was performed to
achieve an adequate margin 1 week postoperatively.
His postoperative course was smooth and the wound
*
Figure 3. Histology of malignant mesothelioma of the tunica
vaginalis testis in a biphasic pattern (hematoxylin & eosin,




Figure 2. Gross inspection of the bivalve specimen. Note the tumor
(arrows) arising from the tunica vaginalis (asterisk) and invading




Figure 4. Immunohistochemistry of malignant mesothelioma of
the tunica vaginalis testis: (A) CK(++); (B) EMA(++); (C)
vimentin (++). (LSAB, 400×.)
Malignant mesothelioma of the tunica vaginalis testis
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healed well. No local recurrence has been noticed at
regular clinic follow-ups for 7 months.
Retrospectively, the patient had short-term occu-
pational exposure to asbestos 40 years ago.
DISCUSSION
Since the first case of malignant mesothelioma at the
tunica vaginalis of testis was described by Barbera and
Rubino in 1957 [1], approximately 100 cases have been
reported. Malignant mesothelioma of pleura, peri-
cardium, and peritoneum are uncommon and malig-
nant mesothelioma originating in the tunica vaginalis
is extremely rare. In the United States the incidence of
malignant mesothelioma is about 11 cases per million
people per year [2]. About 68–85% of the mesothelio-
mas arise in the pleura, 9.1–24.1% in the peritoneum,
and only 0.3–5% in the tunica vaginalis testis [2–4,8].
In patients with malignant mesothelioma at the tunica
vaginalis of the testis, more than two-thirds of the cases
were patients older than 45 years of age with a median
age of 60 years [4], although malignant mesothelioma
has been reported in a 10-year-old child [9]. Patients
usually present with hydrocele (56.3%) and sometimes
a testicular tumor (32.8%) [4]. Although the diagnosis of
malignant mesothelioma of the tunica vaginalis is sel-
dom observed preoperatively, it should be considered
in any patient presenting with scrotal pathology with
a history of exposure to asbestos [5–7]. Direct contact
with asbestos (34.2–41%) [4,10] or a familial occupa-
tional history can significantly increase the risk of dev-
eloping a malignant mesothelioma by a factor of 10
[11–13]. In addition to asbestos, potassium bromate
in drinking water was shown to increase the risk of
developing malignant mesothelioma of the tunica vagi-
nalis testis in an animal model [14] and long-standing
hydrocele was also considered to be a risk factor of
malignant mesothelioma of the tunica vaginalis, as pro-
posed by Gurdal and Erol [15]. The localization of the
tumor is presented with equal incidence in both testi-
cles [4], and the presence of bilateral malignant meso-
thelioma in the tunica vaginalis is very rare, with only
three cases presented before the present case [16–18].
According to different histopathologic traits, malig-
nant mesothelioma has been subclassified into three
types: epithelial type, the most frequently seen (60.8–
75%) in the peritoneal cavity and tunica vaginalis; the
biphasic type, as reported in this case, occurring in the
serosa membrane (25–37.3%); and the mesenchymal
or sarcomatous type, which is found in the pleural
cavity (1.9%) [3,9]. Malignant mesothelioma has an
expansive and infiltrative growth pattern and nearly
40% of the patients presented initially presented with
local invasion, and the two most frequently involved
sites were subtunical connective tissue (25.8%) and
testicular parenchyma (19.4%). Metastasis occurs early
via the lymphatic system to inguinal, para-aortic or
supraclavicular nodes, and was reported in 14.9–31%
of cases [4,19]. In 11 patients with primary metastatic
disease in the study by Plas et al, retroperitoneal lymph
nodes were most involved in five cases, followed by
inguinal nodes in three and iliac nodes in two. In cases
showing disease progression, the common sites of
metastasis were lymph nodes (13.8%), lung (9.7%)
and liver (4.2%) [4]. In the study by Plas et al, tumor
recurrence was more than 60% within 2 years and
over 90% within 5 years [4]. Radical primary resection
may decrease the rate of tumor recurrence.
Univariate analysis to assess the prognostic pa-
rameters revealed a significantly better correlation in
patients of younger age. However, in a multivariate
Cox’s regression model, there was no statistically sig-
nificant result [3]. The mean disease-specific survival
for patients with or without systemic treatment was
26 and 36 months, respectively [20]. Although some
cases were responsive to radiotherapy or chemo-
therapy [21–24], adjuvant treatments such as chemo-
therapy or immunotherapy have limited effects in
advanced disease [4]. Radiotherapy appeared to be
more effective than chemotherapy and as good as the
combination of chemotherapy and radiotherapy in
the patients with metastatic disease [4]. The DNA
hypomethylating agent 5-aza-2’-deoxycytidine may
be effective based on the induction and upregulation
of the expression of cancer/testis antigen [25].
Malignant mesothelioma of tunica vaginalis is 
a rare but often fatal malignancy. It should be consid-
ered a differential diagnosis of inguinoscrotal mass,
particularly in patients with exposure to asbestos.
Despite aggressive surgical procedures or systematic
adjuvant therapies, the prognosis remains poor.
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睪丸白膜鞘惡性間質細胞瘤是一種少見但致命的惡性腫瘤。我們報告一位有石棉接觸
史且局部大範圍侵犯的睪丸白膜鞘惡性間質細胞瘤病人，並且回顧關於目前治療方針
的相關文獻，現今仍以廣泛切除加上放射線治療為主。
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